IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`Civil Action No. 12-cv-435-LPS
`
`
`
`
`
`
`
`
`
`ENZO LIFE SCIENCES, INC.,
`
`
`
`
`
`
`
`Plaintiff,
`
`
`
`
`
`v.
`
`ILLUMINA, INC.,
`
`
`
`
`
`
`
`Defendant.
`
`
`
`
`
`
`
`PLAINTIFF’S SUPPLEMENTAL INFRINGEMENT CHARTS
`FOR ILLUMINA
`
`Pursuant to the Court’s Scheduling Order, Plaintiff Enzo Life Sciences, Inc. ("Plaintiff")
`
`hereby provides its Supplemental Infringement Charts to Defendant Illumina, Inc. ("Illumina").
`
`Plaintiff contends that Illumina, either alone or in conjunction with others, has directly
`
`infringed and continues to directly infringe, literally and/or under the doctrine of equivalents, one
`
`or more claims of U.S. Patent No. 7,064,197 (“the ’197 patent”) (the “Patent-in-Suit”) by
`
`making, using, offering to sell, selling, and/or importing in or into the United States certain
`
`nucleic acid array products, including without limitation:
`
`a) products based upon Direct Hybridization BeadChip technology, including without
`
`limitation, Human HT-12 v4 Expression Bead Chip, HumanWG-6 Expression BeadChip
`
`(all formats), HumanRef-8 Expression BeadChip (all formats), MouseRef-8 v2
`
`Expression BeadChip (all formats), RatRef-12 Expression BeadChip (all formats),
`
`MouseWG-6 v2.0 Expression Bead Chip (all formats), and Whole-Genome DASL HT
`
`Assay, and all other products based upon Direct Hybridization BeadChip technology
`
`(collectively, “Direct Hybridization Assay Products”),
`
`
`
`1
`
`Enzo Exhibit 2134
`BD v. Enzo
`Case IPR2017-00181
`
`Exhibit 2134 Page 1
`
`

`

`b) products based upon Infinium BeadChip technology, including without limitation,
`
`HumanOmni5-Quad (all formats) , HumanOmni2.5S (all formats), HumanOmni2.5-8 (all
`
`formats), HumanOmni1S (all formats), HumanOmniExpress BeadChip (all formats),
`
`HumanCytoSNP-12 (all formats), HumanOmni2.5S+ (all formats), HumanOmni5-Quad+
`
`(all formats), HumanOmniExpress+ (all formats), HumanOmniExpress Multi-Use
`
`BeadChip, InfiniumDx CytoSNP-12 BeadChip Kit, HumanCytoSNP-12 BeadChip Kit,
`
`iSelect HD Custom BeadChip (all formats), iSelect Custom Add-On Content (all
`
`formats), Human Methylation 27 BeadChip (all formats), Human Methylation 450
`
`BeadChip (all formats), BovineHD BeadChip (all formats), BovineSNP50 BeadChip (all
`
`formats), BovineLD BeadChip (all formats), CanineHD BeadChip (all formats),
`
`OvineSNP50 BeadChip (all formats), PorcineSNP60 BeadChip (all formats),
`
`MaizeSNP50 BeadChip (all formats), HumanCNV100W BeadChip Kit, HumanCardio-
`
`Metabo BeadChip Kit, HumanCVD Whole-Genome Genotyping Kit, HumanExome
`
`BeadChip (all formats), HumanExome+ BeadChip (all formats), HumanCore BeadChip
`
`(all formats), HumanCore Exome BeadChip (all formats), HumanCore DNA Analysis
`
`Kits, HumanHap550-Quad+ DNA Analysis Kit, HumanImmuno BeadChip (all formats),
`
`HumanOmniExpressExome BeadChip (all formats), HumanOmniExpressExome+
`
`BeadChip (all formats), HumanLinkage BeadChip (all formats), HumanOmni5Exome
`
`BeadChip (all formats), HumanOmni5Exome+ BeadChip (all formats), HumanCytoSNP-
`
`FFPE-12 BeadChip, HumanOmniExpress-FFPE BeadChip, HumanMethylation450
`
`BeadChip, HumanOmni2.5-Quad Multi-Use BeadChip Kit (all formats),
`
`HumanOmniZhonghua-8 BeadChip Kit (all formats), and all other products based upon
`
`Infinium BeadChip technology (collectively, “Infinium BeadChip Products”),
`
`
`
`2
`
`Exhibit 2134 Page 2
`
`

`

`c) products based upon VeraCode technology, including without limitation, VeraCode GPR
`
`Universal Capture Beads (all formats), VeraCode GPR Carboxyl Beads (all formats),
`
`VeraCode GoldenGate Methylation Analysis BeadPlate, VeraCode GoldenGate
`
`Genotyping Bead Plate, and all other products based upon VeraCode technology
`
`(collectively, “VeraCode Products”),
`
`d) products based upon TruSeq, HiSeq, MiSeq, MiSeqDx, Genome Analyzer, HiSeq X, and
`
`Next Seq sequencing technology, including without limitation, TruSeq Paired-End
`
`Cluster Kit v3-cBot-HS, TruSeq Single-Read Cluster Kit v3-cBot-HS, TruSeq Paired-
`
`End Cluster Kit v2-cBot-GA, TruSeq Single-Read Cluster Kit v2-cBot-GA, TruSeq
`
`Paired-End Cluster Kit v5-CS-GA, TruSeq Single-Read Cluster Kit v5-CS-GA, TruSeq
`
`Rapid Cluster Kit – Paired-End and Single-Read, TruSeq Rapid Duo cBot Sample
`
`Loading Kit, HiSeq X HD Reagent Kit, MiSeq Reagent Kit, MiSeqDx Universal Kit,
`
`NextSeq 500 Kits, TheraSeq Tumor Profiling Test, HiSeq PE Cluster Kit v4 cBot, HiSeq
`
`SR Cluster Kit v4 cBot, and all other products involving sequencing technology
`
`(collectively, “Sequencing Products”), and
`
`e) products based upon GoldenGate BeadChip Assay technology, including without
`
`limitation, GoldenGate Universal-12 BeadChip (all formats) GoldenGate Universal-32
`
`BeadChip (all formats), and all other products based upon GoldenGate BeadChip Assay
`
`technology (collectively, “GoldenGate Assay Products”)
`
`(collectively, the “Accused Products”). Plaintiff further contends that Illumina has actively
`
`induced, and continues to induce, the infringement of one or more claims of the ’197 patent
`
`under 35 U.S.C. § 271(b). At all relevant times, Illumina actively, knowingly, and intentionally
`
`induced others, including without limitation Illumina’s customers to use, make, sell, offer for
`
`
`
`3
`
`Exhibit 2134 Page 3
`
`

`

`sale, and/or import the Accused Products, in a way that Illumina knew or should have known
`
`infringes one or more claims of the ’197 patent. Plaintiff further contends that Illumina’s
`
`infringement of the’197 patent has been, and continues to be, willful.
`
`Plaintiff’s infringement contentions are provided herein without the benefit of full
`
`discovery. The claim charts attached herein as Exhibits A through E identify where each
`
`limitation of the asserted claims of the ’197 patent is found within the Accused Products.
`
`Plaintiff contends that each element of each asserted claim is literally present in the Accused
`
`Products unless otherwise indicated. But to the extent that any claim element is found not to be
`
`literally embodied in the accused instrumentalities, Plaintiff contends that the Accused Products
`
`embody such claim elements under the doctrine of equivalents because there are no substantial
`
`differences for each claim element, and the Accused Products perform substantially the same
`
`function, in substantially the same way, to achieve substantially the same result. To date,
`
`Illumina has not provided non-infringement contentions in this case. Plaintiff reserves the right
`
`to supplement its infringement contentions, including doctrine of equivalents contentions, in
`
`response to Illumina’s non-infringement contentions.
`
`Where a claim element is implemented in the same or substantially the same way for
`
`each product of an Accused Product family (e.g., Direct Hybridization Assay Products), Plaintiff
`
`provides an exemplary illustration or description setting forth specifically where the limitation is
`
`found in the Accused Products, without repeating the same illustration or description for each
`
`version of each Accused Product in the family.
`
`Plaintiff provides these infringement contentions before fulsome discovery and before the
`
`Court’s claim construction ruling. Plaintiff’s infringement contentions are not an admission,
`
`
`
`4
`
`Exhibit 2134 Page 4
`
`

`

`adoption, or waiver of any particular claim construction; Plaintiff reserves all rights with respect
`
`to claim construction.
`
`
`
`These infringement charts are based upon information reasonably and presently available
`
`to Plaintiff through publicly-available information and Illumina’s production of documents to
`
`date. Moreover, depositions are ongoing, and Plaintiff reserves the right to supplement its
`
`contentions based on additional relevant information disclosed during depositions and through
`
`other means of discovery. And to the extent that Plaintiff receives relevant discovery from third
`
`parties, Plaintiff reserves the right to supplement its contentions accordingly. Plaintiff reserves
`
`the right, consistent with its obligations under the Federal Rules of Civil Procedure, the Local
`
`Rules, the Court’s Scheduling Order, and the Default Standard for Discovery, including
`
`Discovery of Electronically Stored Information, to modify, amend, retract, and/or supplement the
`
`infringement charts made herein as additional evidence and information becomes available or as
`
`otherwise appropriate, including the issuance of the Court’s claim construction ruling.
`
`Plaintiff identifies the following asserted claims of the Patent-in-Suit and accused
`
`products, as further explained in Exhibits A through E.
`
`
`Asserted Claims of the ’197 Patent
`1-22, 24, 27-32, 34, 35, 38, 43, 46, 47, 49, 51, 55-
`57, 59, 61-63, 65, 68-72, 74, 75, 78, 81, 84-88, 90,
`94-96, 98, 102, 105, 107, 108, 109, 113, 116, 120,
`122, 124, 127-129, 131, 132, 136-138, 140, 144-
`146, 148, 192-194, 197, 199, 200, 204, 206, 210,
`211, 213, 214, 218, 220, 222, 226-228, 230, 234
`1-22, 24, 27-32, 34, 35, 38, 43, 44, 46, 47, 51, 55-
`57, 59, 61-63, 65, 68-70, 72, 74, 75, 78, 81, 82, 84-
`86, 90, 94-96, 98, 100, 102, 105, 107, 108, 109, 113,
`116, 120, 122-124, 128, 129, 131, 132, 136, 140,
`144-146, 148, 191-194, 196, 197, 199, 206, 210,
`211, 213, 214, 218, 220, 222, 226, 227, 230, 234
`3, 5, 10, 11, 17-22, 29, 30, 32, 38, 39, 43, 44, 46, 47,
`51, 55-57, 59, 65, 72, 78, 80-82, 84-86, 90, 94-96,
`
`
`
`5
`
`
`
`Illumina – Accused Products
`Direct Hybridization Assay Products.
`See Ex. A.
`
`Infinium BeadChip Products. See Ex.
`B.
`
`VeraCode Products. See Ex. C.
`
`Exhibit 2134 Page 5
`
`

`

`
`Asserted Claims of the ’197 Patent
`98, 105, 113, 115, 116, 122-124, 128-129, 131, 132,
`136-138, 140, 144-146, 148, 226-228
`1-23, 25-34, 38-41, 43, 44, 46, 47, 51, 57, 59, 61-63,
`65, 68-70, 72-74, 78, 80-82, 84-86, 90, 96, 98, 100,
`102, 105, 106, 108, 113, 115-120, 122-124, 128,
`129, 131, 132, 136, 140, 146, 148, 150-153, 155-
`157, 161, 168, 174, 176, 178, 180, 185, 187-189,
`191-194, 196, 197, 199, 206, 212, 213, 218, 220-
`227, 230-233
`1-22, 24, 27-32, 34, 35, 38, 43, 44, 46, 47, 51, 57,
`59, 61-63, 65, 68-70, 72, 74, 75, 78, 81, 82, 84-86,
`90, 96, 98, 100, 102, 105, 107, 108, 109, 113, 116,
`120, 122-124, 128, 129, 131, 132, 136, 140, 146,
`148, 191-194, 196, 197, 199, 206, 213, 214, 218,
`220, 222, 226, 227, 230, 234
`
`
`
`Illumina – Accused Products
`
`TruSeq Sequencing Products. See Ex.
`D.
`
`GoldenGate Assay Products. See Ex.
`E.
`
`
`
`
`
`
`
`/s/ Brian E. Farnan
`
`
`Brian E. Farnan (Bar No. 4089)
`Farnan LLP
`919 North Market Street
`12th Floor
`Wilmington, DE 19801
`(302) 777-0300
`(302) 777-0301
`bfarnan@farnanlaw.com
`
`John M. Desmarais (admitted pro hac vice)
`Michael P. Stadnick (admitted pro hac vice)
`Jordan N. Malz (admitted pro hac vice)
`Justin P.D. Wilcox (admitted pro hac vice)
`Peter C. Magic (admitted pro hac vice)
`Joseph C. Akalski (admitted pro hac vice)
`Jessica A. Martinez (admitted pro hac vice)
`Danielle A. Shultz (admitted pro hac vice)
`DESMARAIS LLP
`230 Park Avenue
`New York, NY 10169
`(212) 351-3400
`(212) 351-3401
`
`
`
`
`
`DATED: September 30, 2014
`
`
`
`
`6
`
`Exhibit 2134 Page 6
`
`

`

`jdesmarais@desmaraisllp.com
`mstadnick@desmaraisllp.com
`jmalz@desmaraisllp.com
`jwilcox@desmaraisllp.com
`pmagic@desmaraisllp.com
`jakalski@desmaraisllp.com
`jmartinez@desmaraisllp.com
`dshultz@desmaraisllp.com
`Counsel for Plaintiff
`
`7
`
`
`
`
`
`Exhibit 2134 Page 7
`
`